title: Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.
abstract: OBJECTIVE
  There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed.
  
  
  METHODS
  We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time.
  
  
  RESULTS
  The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18%, 16%, 14%, and 13%, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression.
  
  
  CONCLUSIONS
  The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.
authors.affiliation: Mayo Clinic, Rochester, MN 55905, USA. brown.paul@mayo.edu
authors.forename: Paul D
authors.initials: PD
authors.lastname: Brown
authors.forename: Ashley W
authors.initials: AW
authors.lastname: Jensen
authors.forename: Sara J
authors.initials: SJ
authors.lastname: Felten
authors.forename: Karla V
authors.initials: KV
authors.lastname: Ballman
authors.forename: Paul L
authors.initials: PL
authors.lastname: Schaefer
authors.forename: Kurt A
authors.initials: KA
authors.lastname: Jaeckle
authors.forename: Jane H
authors.initials: JH
authors.lastname: Cerhan
authors.forename: Jan C
authors.initials: JC
authors.lastname: Buckner
mesh_terms: D000328:Adult; D001254:Astrocytoma / Q000150:complications* / Q000401:mortality / Q000473:pathology; D001932:Brain Neoplasms / Q000150:complications* / Q000401:mortality / Q000473:pathology; D003072:Cognition Disorders / Q000145:classification / Q000209:etiology*; D018450:Disease Progression; D005260:Female; D005910:Glioma / Q000150:complications* / Q000401:mortality / Q000473:pathology; D018316:Gliosarcoma / Q000150:complications* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015996:Survival Rate